Breast cancer remains the most common cancer among women, emphasizing the importance of personalized screening and breast health care strategies. With Charlotte’s growing population, the demand for specialized breast imaging tailored to individual risks continues to rise, especially for women with dense breast tissue.

The Importance of Annual Screening Mammograms Starting at Age 40

Routine screening mammograms starting at age 40 significantly reduce breast cancer mortality. Digital Breast Tomosynthesis (DBT), known as 3D mammography, is an advanced screening technology that enhances cancer detection by up to 25% and reduces unnecessary callbacks by about 15%. The American College of Radiology (ACR) recommends DBT as the gold standard for annual breast cancer screening, as it increases detection of smaller, early-stage cancers and leads to better outcomes.

Regular screenings allow physicians to detect breast cancers at earlier stages, leading to less invasive treatments, improved survival rates, and a higher quality of life for patients. Patient adherence to annual mammograms is critical for maximizing these benefits, making ongoing patient education and engagement essential components of personalized breast care.

The Challenge of Dense Breast Tissue

Over 40% of women have dense breast tissue. Dense tissue not only reduces mammographic sensitivity—dropping from about 86% in fatty breasts to around 60% in extremely dense breasts—but also increases a woman’s risk of developing breast cancer by up to fivefold.

In recognition of this, the FDA implemented a breast density mandate in 2024 requiring healthcare providers to inform patients about their breast density status. This regulatory change emphasizes the importance of supplemental screening methods to adequately manage breast health in women with dense tissue.

Tailored Screening for High-Risk Patients

For women identified as having dense breasts or a higher lifetime breast cancer risk (20% or higher), additional screenings are crucial.

Breast MRI:
MRI detects an additional 15–20 cancers per 1,000 women screened. Standard MRIs are typically reserved for high-risk patients due to cost, scan duration, and variable insurance coverage. Despite these limitations, MRI remains a critical tool for high-risk women.

Abbreviated Breast MRI (ABMR):
ABMR provides similar detection rates to standard MRI but offers faster, less expensive scans—usually under 10 minutes. This makes ABMR an excellent option for women with dense breasts who may avoid traditional MRI due to the longer procedure.

Automated Whole Breast Ultrasound Screening (ABUS):
FDA-approved specifically for dense breast screening, ABUS is a non-invasive option that detects 3–4 additional cancers per 1,000 screenings compared to mammography alone. ABUS is ideal for women who cannot undergo MRI due to medical or personal constraints.

Artificial Intelligence is Enhancing Breast Imaging

Artificial Intelligence (AI) is transforming breast imaging by improving accuracy and efficiency. Tools such as ProFound® AI (iCAD) increase cancer detection by 6% and reduce unnecessary recalls by 7%. Newly FDA‑approved technologies like Clarity provide personalized five-year breast cancer risk assessments directly from mammograms, surpassing traditional risk models.

AI is not intended to replace radiologists but to support them—enhancing accuracy, reducing workload, and allowing more time for complex cases and patient communication. Correcting misconceptions about AI’s role is essential in supporting personalized medicine.

Expanding Community Access

To address growing community needs, Charlotte Radiology opened its 18th breast center earlier this year in Fort Mill. Paired with mobile mammography, these centers serve over 140,000 women annually across the greater Charlotte area, offering screening and diagnostic mammography, supplemental screening, and comprehensive breast health services.

The goal is to increase access to advanced breast imaging, reduce travel burdens, and improve adherence to screening recommendations.

Collaboration and Education

Effective personalized breast health requires collaboration among primary care providers, OB-GYNs, and radiologists. Using comprehensive risk assessment tools, providers can recommend individualized imaging strategies based on patient risk factors and preferences.

Educating patients about breast density, personal risks, and available screening options is essential to informed decision-making. Clear educational resources help patients navigate their breast health journey, improving compliance and outcomes.

Looking Ahead

Advancements in breast imaging and AI are transforming personalized breast care, improving early detection and patient outcomes. By continuing to adopt innovative technologies and promoting coordinated care, healthcare providers can ensure women receive high-quality, tailored breast care for years to come.

References

1. Bae MS. Sustainable Benefits of Digital Breast Tomosynthesis Screening. Radiology. 2021 Jan;298(1):58-59
2. Bodewes FTH et al. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022 Dec;66:62-68
3. Stout NK et al. Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density. JAMA Intern Med. 2024 Oct 1;184(10):1222-1231
4. Gao Y et al. Magnetic Resonance Imaging in Screening of Breast Cancer. Radiol Clin North Am. 2021 Jan;59(1):85-98
5. Kuhl CK. Abbreviated Breast MRI: State of the Art. Radiology. 2024 Mar;310(3)
6. Spear GG et al. Automated breast ultrasound: Supplemental screening for average-risk women with dense breasts. Clin Imaging. 2021 Aug;76:15-25
7. Klein Wolterink F et al. Diagnostic performance of 3D automated breast ultrasound (3D‑ABUS) in a clinical screening setting—a retrospective study. Eur Radiol. 2024 Aug;34(8):5451-5460
8. Lee AY et al. Clinical Implementation of AI in Screening Mammography: The Essential Role of Prospective Evaluation. Radiology. 2024 Jun;311(3)
9. Yoon JH et al. Standalone AI for Breast Cancer Detection at Screening Digital Mammography and Digital Breast Tomosynthesis: A Systematic Review and Meta‑Analysis. Radiology. 2023 Jun;307(5)
10. https://www.news-medical.net/news/20250603/Clairity-BREAST-receivesFDA-authorization-for-AI-based-breast-cancer-risk-prediction.aspx